Indication
In adults and children (5 years or older) for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. It is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE).
Medicine details
- Medicine name:
- betula verrucosa (Itulazax)
- SMC ID:
- SMC2904
- Pharmaceutical company
- ALK-Abello Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC